Topotecan (topotecan): Reviews and patient testimonials

Topotecan 1 mg/ml concentrate for solution for infusion

Topotecan monotherapy is indicated for the treatment of:

Patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy.

Patients with relapsed small cell lung cancer [SCLC] for whom re-treatment with the first- line regimen is not considered appropriate.

Topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with Stage IVB disease. Patients with prior exposure to cisplatin require a sustained treatment free interval to justify treatment with the combination.

Topotecan 1mg/ml concentrate for solution for infusion

Topotecan monotherapy is indicated for the treatment of

• patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy.

• patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate.

Topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with Stage IVB disease. Patients with prior exposure to cisplatin require a sustained treatment free interval to justify treatment with the combination.

Topotecan 4 mg Powder for Concentrate for Solution for Infusion

Topotecan monotherapy is indicated for the treatment of:

patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy.

patients with relapsed small cell lung cancer [SCLC] for whom re-treatment with the first- line regimen is not considered appropriate.

Topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with Stage IVB disease. Patients with prior exposure to cisplatin require a sustained treatment free interval to justify treatment with the combination.

Topotecan Actavis 1 mg powder for concentrate for solution for infusion

Topotecan monotherapy is indicated for the treatment of patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate.

Topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with Stage IVB disease. Patients with prior exposure to cisplatin require a sustained treatment free interval to justify treatment with the combination.

Topotecan Actavis 4 mg powder for concentrate for solution for infusion

Topotecan monotherapy is indicated for the treatment of patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate.

Topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with Stage IVB disease. Patients with prior exposure to cisplatin require a sustained treatment free interval to justify treatment with the combination.

Topotecan Hospira 4 mg/4 ml concentrate for solution for infusion

Topotecan monotherapy is indicated for the treatment of:

• patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy

• patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate.

Topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with Stage IVB disease. Patients with prior exposure to cisplatin require a sustained treatment-free interval to justify treatment with the combination.

Route of administration: Injectable
Molecule: topotecan